Singapore markets closed

Straits Times Index
3,313.48
+8.49(+0.26%)
Nikkei
38,787.38
-132.88(-0.34%)
Hang Seng
19,553.61
+177.08(+0.91%)
FTSE 100
8,420.26
-18.39(-0.22%)
Bitcoin USD
66,887.52
+1,775.64(+2.73%)
CMC Crypto 200
1,365.48
-8.36(-0.61%)

Acurx Pharmaceuticals Inc (3ZO.BE)

Berlin - Berlin Delayed price. Currency in EUR

Add to watchlist

2.0550

+0.0500

(+2.49%)

At close: 08:08PM CEST

All

GuruFocus.com
Acurx Pharmaceuticals Inc (ACXP) Q1 2024 Earnings Call Transcript Highlights: Key Financial and ...
Explore the financial dynamics and strategic clinical advancements as ACXP progresses with its Phase III trials.
Thomson Reuters StreetEvents
Q1 2024 Acurx Pharmaceuticals Inc Earnings Call
Q1 2024 Acurx Pharmaceuticals Inc Earnings Call
PR Newswire
Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced the successful outcome of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of ibezapolstat for the treatment of C. difficile Infection into Phase 3 studies based on the recently completed Phase 2 clinical trial results.